COVID-19: Australian team develops its first vaccine candidate

Organisation: Position: Deadline Date: Location:

A University of Queensland team has met a key milestone in their fast-tracked research to develop a vaccine for the coronavirus, COVID-19, says a Medical Xpress report. In just three weeks, the team of researchers has created their first vaccine candidate in the laboratory and will move immediately into further development before formal pre-clinical testing.

The proof-of-concept milestone comes after the project’s announcement on 24 January as part of the Coalition for Epidemic Preparedness Innovations (CEPI) rapid response programme.

UQ vice-chancellor and president Professor Peter Høj AC said the team has shown considerable progress in line with the highly accelerated time frame of the rapid response program, and the long hours in the lab have paid off with this achievement. “There is still extensive testing to ensure that the vaccine candidate is safe and creates an effective immune response, but the technology and the dedication of these researchers means the first hurdle has been passed,” Høj said.

The work in the lab shows the feasibility of using UQ’s ‘molecular clamp’ technology to engineer a vaccine candidate that could be more readily recognised by the immune system, triggering a protective immune response. The next stage is to produce this on a larger scale needed for additional testing, to determine its effectiveness against the virus.

Researchers said the early research had gone “as expected” and the material created had the properties which allowed the team to proceed with vaccine development.

The group continues to work to a much-accelerated timetable to keep on track for investigational clinical testing after the middle of the year.

Full Medical Xpress report

Receive Medical Brief's free weekly e-newsletter



Related Posts

Thank you for subscribing to MedicalBrief


MedicalBrief is Africa’s premier medical news and research weekly newsletter. MedicalBrief is published every Thursday and delivered free of charge by email to over 33 000 health professionals.

Please consider completing the form below. The information you supply is optional and will only be used to compile a demographic profile of our subscribers. Your personal details will never be shared with a third party.


Thank you for taking the time to complete the form.